Myriad Genetics (MYGN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Myriad Genetics Revenue Highlights

Latest Revenue (Y)

$753.20M

Latest Revenue (Q)

$213.30M

Main Segment (Y)

Testing Revenue

Main Geography (Y)

UNITED STATES

Myriad Genetics Revenue by Period

Myriad Genetics Revenue by Year

Date	Revenue	Change
2023-12-31	$753.20M	11.03%
2022-12-31	$678.40M	-1.77%
2021-12-31	$690.60M	23.99%
2020-12-31	$557.00M	-34.56%
2020-06-30	$851.10M	-
2019-06-30	$851.10M	10.16%
2018-06-30	$772.60M	0.16%
2017-06-30	$771.40M	2.33%
2016-06-30	$753.80M	4.25%
2015-06-30	$723.10M	-7.08%
2014-06-30	$778.22M	26.92%
2013-06-30	$613.16M	23.62%
2012-06-30	$496.00M	23.36%
2011-06-30	$402.08M	10.87%
2010-06-30	$362.65M	11.06%
2009-06-30	$326.53M	-2.13%
2008-06-30	$333.63M	112.33%
2007-06-30	$157.13M	37.49%
2006-06-30	$114.28M	38.68%
2005-06-30	$82.41M	45.47%
2004-06-30	$56.65M	-11.93%
2003-06-30	$64.32M	19.47%
2002-06-30	$53.84M	19.21%
2001-06-30	$45.16M	32.78%
2000-06-30	$34.01M	34.44%
1999-06-30	$25.30M	9.05%
1998-06-30	$23.20M	52.63%
1997-06-30	$15.20M	130.30%
1996-06-30	$6.60M	-

Myriad Genetics generated $753.20M in revenue during NA 2023, up 11.03% compared to the previous quarter, and up 88.50% compared to the same period a year ago.

Myriad Genetics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$213.30M	0.85%
2024-06-30	$211.50M	4.60%
2024-03-31	$202.20M	2.85%
2023-12-31	$196.60M	2.45%
2023-09-30	$191.90M	4.58%
2023-06-30	$183.50M	1.27%
2023-03-31	$181.20M	1.91%
2022-12-31	$177.80M	13.68%
2022-09-30	$156.40M	-12.77%
2022-06-30	$179.30M	8.73%
2022-03-31	$164.90M	2.55%
2021-12-31	$160.80M	-3.89%
2021-09-30	$167.30M	-11.67%
2021-06-30	$189.40M	9.42%
2021-03-31	$173.10M	11.97%
2020-12-31	$154.60M	6.47%
2020-09-30	$145.20M	55.79%
2020-06-30	$93.20M	-43.17%
2020-03-31	$164.00M	-15.94%
2019-12-31	$195.10M	4.72%
2019-09-30	$186.30M	-13.51%
2019-06-30	$215.40M	-0.55%
2019-03-31	$216.60M	-0.09%
2018-12-31	$216.80M	7.17%
2018-09-30	$202.30M	0.70%
2018-06-30	$200.90M	3.82%
2018-03-31	$193.50M	-0.26%
2017-12-31	$194.00M	2.00%
2017-09-30	$190.20M	-5.14%
2017-06-30	$200.50M	1.83%
2017-03-31	$196.90M	0.20%
2016-12-31	$196.50M	10.70%
2016-09-30	$177.50M	-4.83%
2016-06-30	$186.50M	-2.10%
2016-03-31	$190.50M	-1.45%
2015-12-31	$193.30M	5.34%
2015-09-30	$183.50M	-3.36%
2015-06-30	$189.88M	5.50%
2015-03-31	$179.99M	-2.39%
2014-12-31	$184.39M	9.21%
2014-09-30	$168.84M	-10.56%
2014-06-30	$188.77M	3.19%
2014-03-31	$182.92M	-10.36%
2013-12-31	$204.06M	0.79%
2013-09-30	$202.47M	16.28%
2013-06-30	$174.12M	11.28%
2013-03-31	$156.47M	4.92%
2012-12-31	$149.14M	11.77%
2012-09-30	$133.44M	0.35%
2012-06-30	$132.97M	2.46%
2012-03-31	$129.78M	5.67%
2011-12-31	$122.81M	11.19%
2011-09-30	$110.45M	2.83%
2011-06-30	$107.41M	4.92%
2011-03-31	$102.37M	1.93%
2010-12-31	$100.44M	9.34%
2010-09-30	$91.86M	-2.20%
2010-06-30	$93.93M	3.41%
2010-03-31	$90.83M	-2.09%
2009-12-31	$92.77M	8.98%
2009-09-30	$85.12M	5.07%
2009-06-30	$81.01M	-7.40%
2009-03-31	$87.49M	3.69%
2008-12-31	$84.38M	14.56%
2008-09-30	$73.65M	-55.86%
2008-06-30	$166.86M	170.15%
2008-03-31	$61.77M	-

Myriad Genetics generated $213.30M in revenue during Q3 2024, up 0.85% compared to the previous quarter, and up 116.24% compared to the same period a year ago.

Myriad Genetics Revenue Breakdown

Myriad Genetics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Jun 20	Jun 19	Jun 18
Testing Revenue	$753.20M	-	-	-
Molecular Diagnostic Prolaris Testing	-	$24.70M	$25.50M	-
Molecular Diagnostic Endo Predict Testing	-	$10.50M	$10.40M	-
Molecular Diagnostic Genesight Testing	-	$74.10M	$112.60M	-
Molecular Diagnostic Other Testing	-	$14.40M	$8.00M	-
Molecular Diagnostic Prenatal Testing	-	$76.70M	$104.90M	-
Pharmaceutical And Clinical Services	-	$51.70M	$61.70M	$53.30M
Molecular Diagnostic Testing	-	$586.90M	$789.40M	$719.30M
Molecular Diagnostic Hereditary Cancer Testing	-	$347.40M	$479.70M	-
Molecular Diagnostic Vectra Testing	-	$39.10M	$48.30M	-

Myriad Genetics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Testing Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Jun 23	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
Non-US	$8.70M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UNITED STATES	$27.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diagnostics	-	$161.70M	$177.10M	$157.80M	$130.50M	$150.50M	$177.60M	$170.40M	$200.50M	$203.00M	$189.00M	$179.70M	-	-	-
Other Segments	-	$5.60M	$12.30M	$15.30M	$14.70M	-	-	-	-	-	-	-	-	-	-
Molecular Diagnostic Genesight Testing	-	-	-	-	-	$8.50M	$29.80M	-	-	-	-	-	-	-	-
Molecular Diagnostic Endo Predict Testing	-	-	-	-	-	$2.20M	$3.00M	-	-	-	-	-	-	-	-
Molecular Diagnostic Hereditary Cancer Testing	-	-	-	-	-	$39.80M	$119.00M	-	-	-	-	-	-	-	-
Molecular Diagnostic Other Testing	-	-	-	-	-	$4.30M	$1.70M	-	-	-	-	-	-	-	-
Molecular Diagnostic Prenatal Testing	-	-	-	-	-	$16.60M	$24.90M	-	-	-	-	-	-	-	-
Molecular Diagnostic Prolaris Testing	-	-	-	-	-	$4.60M	$6.30M	-	-	-	-	-	-	-	-
Molecular Diagnostic Testing	-	-	-	-	-	$83.30M	$196.90M	$187.60M	-	-	-	-	-	-	-
Molecular Diagnostic Vectra Testing	-	-	-	-	-	$7.30M	$12.20M	-	-	-	-	-	-	-	-
Pharmaceutical And Clinical Services	-	-	-	-	-	$9.90M	$18.50M	$13.30M	-	-	-	-	-	-	-
All Other Segments	-	-	-	-	-	-	$13.50M	$17.50M	$15.90M	$16.10M	$13.80M	$13.30M	$13.80M	-	-

Myriad Genetics's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: UNITED STATES (75.83%), and Non-US (24.17%).

Myriad Genetics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21
Non-US	$81.50M	$44.10M	$40.50M
UNITED STATES	$671.70M	$84.50M	$24.20M

Myriad Genetics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (89.18%), and Non-US (10.82%).

Quarterly Revenue by Country

Country	Sep 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Mar 20	Dec 19	Sep 19	Mar 19	Dec 18	Sep 18
Non-US	$17.30M	$19.70M	$8.70M	$8.50M	$20.80M	$10.60M	$12.00M	$12.80M	$10.00M	$11.50M	$11.10M	$3.60M	$200.00K	-	-	-	-	-	-
UNITED STATES	$196.00M	$172.20M	$27.30M	$28.80M	$157.00M	$20.20M	$21.50M	$19.70M	$16.50M	$21.40M	$10.70M	$13.50M	$9.50M	$153.00M	$182.30M	$174.70M	$204.40M	$205.80M	$191.60M
Non Us	-	-	-	-	-	-	-	-	-	-	-	-	-	$11.00M	$12.90M	$11.70M	$12.20M	$11.00M	$10.70M

Myriad Genetics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (91.89%), and Non-US (8.11%).

Myriad Genetics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ILMN	Illumina	$4.37B	$1.10B
EXAS	Exact Sciences	$2.76B	$706.78M
MEDP	Medpace	$2.11B	$558.57M
QGEN	Qiagen	$1.97B	$458.80M
RDNT	RadNet	$1.83B	$19.22M
NTRA	Natera	$1.70B	$476.06M
SHC	Sotera Health	$1.10B	$254.52M
NEOG	Neogen	$924.22M	$220.98M
MYGN	Myriad Genetics	$753.20M	$213.30M
GH	Guardant Health	$739.02M	$203.47M
CDNA	CareDx	$333.79M	$84.69M
CSTL	Castle Biosciences	$332.07M	$87.99M
TWST	Twist Bioscience	$312.97M	$92.79M
ACRS	Aclaris Therapeutics	$18.72M	$9.21M
PSNL	Personalis	-	$16.80M

MYGN Revenue FAQ

What is Myriad Genetics’s yearly revenue?

Myriad Genetics's yearly revenue for 2023 was $753.2M, representing an increase of 11.03% compared to 2022. The company's yearly revenue for 2022 was $678.4M, representing a decrease of -1.77% compared to 2021. MYGN's yearly revenue for 2021 was $690.6M, representing an increase of 23.99% compared to 2020.

What is Myriad Genetics’s quarterly revenue?

Myriad Genetics's quarterly revenue for Q3 2024 was $213.3M, a 0.85% increase from the previous quarter (Q2 2024), and a 11.15% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $211.5M, a 4.60% increase from the previous quarter (Q1 2024), and a 15.26% increase year-over-year (Q2 2023). MYGN's quarterly revenue for Q1 2024 was $202.2M, a 2.85% increase from the previous quarter (Q4 2023), and a 11.59% increase year-over-year (Q1 2023).

What is Myriad Genetics’s revenue growth rate?

Myriad Genetics's revenue growth rate for the last 3 years (2021-2023) was 9.06%, and for the last 5 years (2019-2023) was -11.50%.

What are Myriad Genetics’s revenue streams?

Myriad Genetics's revenue streams in c 23 are Testing Revenue

What is Myriad Genetics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Myriad Genetics was Testing Revenue. This segment made a revenue of $753.2M, representing 100.00% of the company's total revenue.